Literature DB >> 9186561

Viridiofungins, novel inhibitors of sphingolipid synthesis.

S M Mandala1, R A Thornton, B R Frommer, S Dreikorn, M B Kurtz.   

Abstract

Viridiofungins are broad spectrum antifungal agents that inhibit the squalene synthase in vitro, but do not specifically inhibit fungal ergosterol synthesis in whole cells, indicating a different mode of action for antifungal activity. In this report, we show that viridiofungins are potent in vitro inhibitors of serine palmitoyltransferase, the first committed enzyme in sphingolipid biosynthesis, and their antifungal activity is due to inhibition of sphingolipid synthesis. Additional related components with the same mode of action were isolated from the producing culture, Trichoderma viride, and inhibition of the serine palmitoyltransferase and antifungal activity is presented.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186561     DOI: 10.7164/antibiotics.50.339

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  9 in total

Review 1.  Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.

Authors:  Alfred H Merrill
Journal:  Chem Rev       Date:  2011-09-26       Impact factor: 60.622

Review 2.  Synthetic studies of viridiofungins, broad-spectrum antifungal agents and serine palmitoyl transferase inhibitors.

Authors:  Naoya Kumagai; Masakatsu Shibasaki
Journal:  J Antibiot (Tokyo)       Date:  2017-09-27       Impact factor: 2.649

3.  Binding modes of zaragozic acid A to human squalene synthase and staphylococcal dehydrosqualene synthase.

Authors:  Chia-I Liu; Wen-Yih Jeng; Wei-Jung Chang; Tzu-Ping Ko; Andrew H-J Wang
Journal:  J Biol Chem       Date:  2012-04-03       Impact factor: 5.157

Review 4.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

5.  A stereoselective synthesis of (-)-viridiofungin A utilizing a TiCl(4)-promoted asymmetric multicomponent reaction.

Authors:  Arun K Ghosh; Jorden Kass
Journal:  Org Lett       Date:  2011-12-23       Impact factor: 6.005

Review 6.  Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.

Authors:  M E Cardenas; M C Cruz; M Del Poeta; N Chung; J R Perfect; J Heitman
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

7.  Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids.

Authors:  Visesato Mor; Antonella Rella; Amir M Farnoud; Ashutosh Singh; Mansa Munshi; Arielle Bryan; Shamoon Naseem; James B Konopka; Iwao Ojima; Erika Bullesbach; Alan Ashbaugh; Michael J Linke; Melanie Cushion; Margaret Collins; Hari Krishna Ananthula; Larry Sallans; Pankaj B Desai; Nathan P Wiederhold; Annette W Fothergill; William R Kirkpatrick; Thomas Patterson; Lai Hong Wong; Sunita Sinha; Guri Giaever; Corey Nislow; Patrick Flaherty; Xuewen Pan; Gabriele Vargas Cesar; Patricia de Melo Tavares; Susana Frases; Kildare Miranda; Marcio L Rodrigues; Chiara Luberto; Leonardo Nimrichter; Maurizio Del Poeta
Journal:  mBio       Date:  2015-06-23       Impact factor: 7.867

Review 8.  Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols.

Authors:  Sarah T Pruett; Anatoliy Bushnev; Kerri Hagedorn; Madhura Adiga; Christopher A Haynes; M Cameron Sullards; Dennis C Liotta; Alfred H Merrill
Journal:  J Lipid Res       Date:  2008-05-21       Impact factor: 5.922

Review 9.  Sphingolipid biosynthesis in man and microbes.

Authors:  Peter J Harrison; Teresa M Dunn; Dominic J Campopiano
Journal:  Nat Prod Rep       Date:  2018-09-19       Impact factor: 13.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.